George W Buchman Ph.D

Dr. Buchman brings more than 30 years of highly cross-functional experience in the biotechnology industry to Paragon Gene Therapy, including roles in molecular diagnostics, R&D, leadership roles in manufacturing, fermentation and process development, global program management, business development and custom protein, VLP and viral vector development and production. At Paragon, George has held Principal Investigator roles for vaccine production including Ebola and second-generation HPV. He directs an industry leading development team specialized in broad offerings including viral vectors, native and oncolytic viruses, as well as gene editing and vaccine technologies, and analytical development, among other disciplines. Before joining Paragon in 2014, George spent 8 years at Chesapeake PERL (C-PERL) as Vice President of Operations and Chief Scientific Officer, primarily as Principal Investigator on multiple grants and contracts across a number of federal agencies, and as subcontractor to Prime Contractors for the custom production of influenza and bioactive proteins, and VLPs. Prior to C-PERL, George worked for 5 years in global program management and business development roles at Celera Genomics and GeneLogic Corporation, both informatics businesses. He started in his post-doctoral career at Life Technologies, where he worked in a series of cross-functional roles and was a member of the Global Leadership team. George provided oversight for build-out of a cGMP-compliant protein production facility, and gained substantial experience directing groups in DNA and protein-related manufacturing and process development.